What is CereVasc?
Located within the Massachusetts healthcare hub, CereVasc, Inc. is dedicated to pioneering minimally invasive treatments for neurological conditions. The company's flagship product, the eShunt System, utilizes a novel percutaneous transvenous-transdural method to access the central nervous system. This patented system is designed to offer the first minimally invasive therapeutic option for communicating hydrocephalus (CH), featuring an endovascularly implantable cerebrospinal fluid shunt and delivery components that aim to bypass traditional surgical interventions.
How much funding has CereVasc raised?
CereVasc has raised a total of $198.9M across 3 funding rounds:
Series A
$43.9M
Series B
$70M
Series C
$85M
Series A (2020): $43.9M with participation from ATON Partners LLC and Perceptive Xontogeny Venture Fund
Series B (2024): $70M led by Bain Capital Life Sciences and Perceptive Xontogeny Venture Fund
Series C (2026): $85M supported by Johnson & Johnson Innovation and Piper Sandler
Key Investors in CereVasc
ATON Partners LLC
ATON Partners LLC is an investment firm that likely focuses on strategic capital allocation within the healthcare and technology sectors, given CereVasc's profile.
Perceptive Xontogeny Venture Fund
Perceptive Xontogeny Venture Fund is a venture capital firm specializing in early-stage investments, particularly within the life sciences and biotechnology sectors, indicating a strong belief in CereVasc's innovative medical device technology.
Johnson & Johnson Innovation
Johnson & Johnson Innovation is a global entity focused on advancing human health through groundbreaking medical solutions, partnering with companies like CereVasc to bring transformative healthcare technologies to market.
What's next for CereVasc?
The substantial enterprise-level funding, culminating in the recent major strategic investment, positions CereVasc for accelerated growth and the advancement of its eShunt System through clinical trials and toward market readiness. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and support regulatory submissions. The company's focus on a minimally invasive solution for a significant unmet need in neurological care suggests a strategic trajectory aimed at capturing a substantial share of the neuro-interventional market.
See full CereVasc company page
